Date：27 July (Wednesday)
Time: 09:00 – 10:30 (GMT+8)
Partner and Europe Pharma & Life Sciences Leader
PwC Strategy& (Germany) GmbH
Dr. Thomas Solbach is a Partner at Strategy& Germany, PwC’s strategy consulting business, based in Frankfurt. He co-leads the European Commercial Practice in Pharma and Life Sciences and supports global pharmaceutical, biotech and healthcare companies in building game-changing, differentiating strategies and capabilities, as well as in the optimization of operating models. Thomas is a leading practitioner in precision medicine, patient-centered health ecosystems, innovative diagnostics, and clinically relevant real-world evidence.
Dr. Thomas Solbach is a frequent speaker at healthcare conferences and author of several studies.
Prior to joining Strategy&, he conducted pharma-related research in oncology and cardiovascular diseases. He completed his studies of Molecular Medicine at the University of Erlangen and the University of Oxford, and holds a PhD in the area of Health Economics.
In the past years, healthcare systems and the pharmaceutical industry have undergone tremendous changes given technological, regulatory, and socioeconomic disruptions. Covid-19 has further intensified and catalysed these changes in healthcare systems and healthcare delivery.
Among others, regulators paved the way for more dynamic and faster decision-making, approved novel technologies including digital health solutions and created new reimbursement pathways. In parallel, medical and biological research has made breakthroughs with emerging technologies including in-silico protein folding prediction, novel cell therapies and other treatment platforms. With those trends materializing, borders between industries continue to blur. This convergence of healthcare, technology, and retail & consumer industries will lead to what we call the LIFEcare system. The critical question for each player in that new normal will be: Are you prepared and what is your right to be successful in this changing future?